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ABSTRACT
Targeted cancer therapeutics are promised to have a major impact on cancer
treatment and survival. Successful application of these novel treatments requires a
molecular definition of a patient’s disease typically achieved through the use of tissue
biopsies. Alternatively, allowing longitudinal monitoring, biomarkers derived from
blood, isolated either from circulating tumor cell derived DNA (ctcDNA) or circulating
cell-free tumor DNA (ccfDNA) may be evaluated. In order to use blood derived
templates for mutational profiling in clinical decisions, it is essential to understand
the different template qualities and how they compare to biopsy derived template DNA
as both blood-based templates are rare and distinct from the gold-standard. Using
a next generation re-sequencing strategy, concordance of the mutational spectrum
was evaluated in 32 patient-matched ctcDNA and ccfDNA templates with comparison
to tissue biopsy derived DNA template. Different CTC antibody capture systems for
DNA isolation from patient blood samples were also compared. Significant overlap
was observed between ctcDNA, ccfDNA and tissue derived templates. Interestingly,
if the results of ctcDNA and ccfDNA template sequencing were combined, productive
samples showed similar detection frequency (56% vs 58%), were temporally
flexible, and were complementary both to each other and the gold standard. These
observations justify the use of a multiple template approach to the liquid biopsy,
where germline, ctcDNA, and ccfDNA templates are employed for clinical diagnostic
purposes and open a path to comprehensive blood derived biomarker access.

imaging technologies and disease-specific pathologic
characterization of tissue biopsies typically obtained at time
of primary surgery. This generic and standard approach
does not support effective cures in the advanced setting
primarily because of the inability of cytotoxic therapy to

INTRODUCTION
Cancer remains one of the leading causes
of morbidity worldwide. Treatment decisions and
response monitoring is historically dependent on serial
www.impactjournals.com/oncotarget
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deal with tumor heterogeneity. In the last few years, the
emergence of next generation sequencing tools has cast a
very different light on the nature of tumor clonality with
the ability to build an emerging model describing a much
more heterogeneous disease than previously understood [1,
2]. This raises problems in determining the best diagnostic
approach when dealing with a disease characterized
by a dynamic plasticity that could be not captured in its
complexity by the simple molecular snapshot offered
by a one-time tissue biopsy. The traditional biopsy is
increasingly understood as too restrictive to monitor
relevant changes in progression and resistance because it
represents a “geographically” and “temporally” restricted
sample with implications in patients’ management [3].
This has driven the development of various “liquid biopsy”
technologies that seek to address the need for monitoring
tools that use the specific readout of DNA based biomarkers
to monitor changes in tumor profile [4].
The earliest version of a liquid biopsy was built
on careful enumeration of a small number of cells that
could be found in the blood of patients with epithelial
cancers [5, 6]. In the most mature form, this resulted in
the FDA approved CellSearch™ test. Using EpCAM to
recover, and intracellular expression of Cytokeratin to
detect a population of cells, it was shown this population
of circulating epithelial cells predict worse outcome,
faster disease progression, and increased likelihood
of metastatic events [7]. This population came to be
known as circulating tumor cells (CTC). However there
were several problems demonstrated with the approach.
Molecular evaluation has shown some but not all of the
cells bear molecular hallmarks of cancer [8-10]. Also,
this restricted phenotypic definition of a tumor cell was
described prognostically and so excluded many classes of
informative cells [11-14]. As a result, CTC enumeration
using these legacy definitions frequently returns limited
or absent numbers of cells. Maybe most importantly, CTC
counting has been ineffective at demonstrating clinical
utility in the advanced setting for individual patients [15].
Despite those limitations, because of their detection in a
peripheral blood sample, circulating tumor cells provide
an attractive source of genetic material for longitudinal
monitoring in view of the minimal invasiveness of a blood
draw and their potential to reflect the molecular profile of
the metastatic cell population [8, 16-17].
Circulating cell-free DNA was identified in 1948
in the plasma and derives from both normal and diseased
tissue [18]. Clinical studies have shown ccfDNA can
act as a suitable template for cancer monitoring and
management [19-22]. Unlike circulating tumor cells,
studies suggest ccfDNA representation aligns with
disease burden and disease type [23]. As such, the reasons
ctcDNA and ccfDNA are found in blood are different
with CTC representing the mobile cellular aspect of a
tumor while ccfDNA is produced chiefly as a product of
apoptosis [24, 25].
www.impactjournals.com/oncotarget

In summary, two primary sources of DNA template
are available from cancer patient blood samples. These
templates have been interrogated for specific known
mutations using ultra sensitive PCR based techniques
[26]. However the mutational spectrum from these two
sample types have never been compared because of the
signal to noise challenge for enriching rare tumor cells
and a clear comparison of template quality has never been
performed. Furthermore, there has not been a concordance
study between ctcDNA, ccfDNA, and formalin fixed,
paraffin embedded tissue (FFPE) from the same patient
and blood draw using sequencing. One reason for this
has been technical. Previous studies to compare the
two templates have reached different conclusions based
on technical limitations for enrichment techniques or
based on evaluation with molecular tools that are not
directly comparable [21]. Recent advances in separation
technologies have provided a solution for this technical
problem [27]. The LiquidBiopsy® platform (Cynvenio
Biosystems), allows for isolation of useful amounts of
ccfDNA and ctcDNA from the same patient blood draw.
Typically the amount of ccfDNA and ctcDNA recovered
per blood draw is sufficient to produce patient matched
NGS libraries. The use of NGS means tumor cells and
tumor derived DNA fragments can be defined as mutation
bearing events and can therefore be directly compared. In
this report we describe a generalizable strategy using NGS
on 32 matched FFPE, ccfDNA and ctcDNA samples from
clinical samples.

RESULTS
Characterization of clinical samples
In this study, patients were recruited based on a
confirmed diagnosis of metastatic breast cancer. The
samples were collected at baseline, either before start of
a new therapy or at completion of staging diagnosis. A
tissue biopsy specimen of the metastatic recurrence was
mandatory. The patients were predominantly female (97%)
and all had stage IV disease. The remaining characteristics
are shown in Table 1. Formalin-fixed, paraffin-embedded
(FFPE) tumor specimens were obtained for all patients
for whom sufficient tissue remained in the pathology
block of the metastatic lesion. Of 32 patients, 7 had either
insufficient DNA recovered for sequencing, too little or
no tumor component to the biopsy or no remaining biopsy
tissue. 25 of 32 samples were successfully evaluated.

Target recovery and extraction of ctcDNA and
ccfDNA template
EpCAM is the legacy marker for recovery of CTC
in breast cancer. To expand the definition of cells that
can be functionally recovered, a cocktail of antibodies
that recognize surface receptors in addition to EpCAM
26725

Oncotarget

Table 1: Characteristics of normal and metastatic cancer samples analyzed for peripheral templates
Characteristic

Number

Range (%)

Normal Controls
Number
total Normals

31

Median

48

30-74

Male

13

(42%)

Female

15

(48%)

Unknown

3

(10%)

Age (years)
Sex

Metastatic Cancer Samples
Number
Total

32

Median

55

36-82

Male

1

(3%)

Female

31

(97%)

Luminal A

15

(47%)

Luminal B

6

(19%)

Her2

4

(13%)

TNBC

6

(19%)

Unknown

1

(3%)

Stage IV

31

(97%)

Unknown

1

(3%)

Median

4

0-13

Synchronous (≤6 months)

17

0-18 weeks (53%)

Asynchronous (≥6 months)

14

31-240 weeks (44%)

Not available

3

(3%)

Age (years)
Sex

BC subtype

Pathologic stage

No. of lines of Therapy
Sampling Interval

were evaluated. Tumor cells representing the five
major subtypes of breast cancer were added to 7.5mL
normal healthy blood samples and recovered using the
LiquidBiopsy system (Figure 1). The five subtypes;
Basal, Claudin low, Her2, Luminal A and Luminal B,
were each represented by two different well characterized
www.impactjournals.com/oncotarget

tumor cell lines [28]. The efficiency of recovery using
EpCAM was compared to capture with EpCAM, Her2,
and Trop2 (an epithelial/mesenchymal transition profile
(EMT)). Recovery (top graph) and purity (bottom graph)
of samples engineered with 90c/mL of each cell line
were determined. The same cell lines were evaluated by
26726
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FACs for expression of the three markers. EpCAM only
based recovery gave between <1% and 103% recovery
of engineered samples. Consistent with patterns of
expression, Claudin low and Basal type breast cancer
cell lines demonstrated the least recovery with EpCAM
alone. Addition of Her2 and Trop2 specific antibodies
incremented recovery of target cells when those receptors
were expressed. So HCC-1569, MDA-MD-231 and HCC1937 cell recovery was significantly improved by the pool
of antibodies. There is a consistent inhibition of capture
of MCF7 cells when the mixture of antibodies is used
possibly due to stearic hinderance. Despite this, when

a receptor is available for capture, the 90c/mL samples
were recovered with an average efficiency of 77% using
the EMT cocktail. Critically, with the exception of HCC1395 which demonstrated no significant capture with
either reagent set, 90 tumor cells/mL could be enriched
to an average purity of between 29% and 67% from
whole blood (see bottom graph). Thus, the LiquidBiopsy
platform could reproducibly enrich target cells on the
order of 105-106 fold enrichment.
Applying this approach to clinical samples, tumor
cell populations were enriched using EpCAM targeted
capture and compared to EMT targeted capture. This

Figure 1: Tumor cells representing the five major subtypes of breast cancer were recovered from 7.5mL blood samples
using the LiquidBiopsy system. The efficiency of recovery using EpCAM compared to capture with EpCAM, Her2, and Trop2 (top
graph) and purity (bottom graph) are shown. Each sample was evaluated in quadruplicate and the bars represent means (+ 1 SD) The same
cell lines were evaluated by FACs for control IgG1 (purple), EpCAM (blue), Trop2 (red) or Her2 expression (green) as detected using
Streptavidin-FITC.
www.impactjournals.com/oncotarget
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enrichment protocol was applied to 32 serial patient
samples from metastatic breast cancer who were otherwise
not selected for elevated CTC numbers. EpCAM based
enrichment served as a control and was compared to
cell populations selected with EMT cocktail. 32 blood
samples were processed for EpCAM only with an average
recovered purity of 7.7% Cytokeratin positive (CK+) cells.
By comparison, EMT selection enriched populations with
on average 8.8% cytokeratin positive cell populations with
a larger range of cells than EpCAM selected (see Table 2).
Importantly, the median number of CK+ cells recovered
from EMT capture was almost three times elevated
over EpCAM alone. (median of 23.5 cells/7.5mL vs 8.0
cells/7.5mL for EMT and EpCAM respectively). Also, the
median number of CD45+ non-target cells captured was
116 and 172 cells respectively. This background is relevant
to a sequencing test that supports detection of mutations
present at >1%. ccfDNA sample was purified from the
same tube of blood. The average concentration of ccfDNA
recovered from fixed plasma samples was 7.3 ng/mL.

The SNV-SF was calculated on ccfDNA and
circulating cell DNA recovered from 29 normal healthy
volunteers. This analysis revealed a three-fold difference
in the number of alterations observed in a known negative
sample set (Figure 2). Thus, there is a noise variable
manifest in ccfDNA as altered sequence that is based on
the compartment of the DNA template rather than the
sequencing reaction or the sequencing platform. A twotailed Wilcoxon rank sum test measured a p value of
0.0009. If we assume that all SNVs detected in healthy
donors are false positives then there is a 3-fold higher
noise in the ccfDNA samples compared to the matched
circulating cell DNA sample. This difference is detected
on template fixed in the same sample tube, for the same
time and measured with the same test. It therefore suggests
the noise variable in ccfDNA is a biological noise rather
than a system or assay noise. As a result, the primary
comparison of ccfDNA and ctcDNA was restricted to
the panel of COSMIC validated SNVs mapping to the
AmpliSeq Hotspot panel in the CLIA validated test. These
restrictions allowed de novo identification of template
associated mutations across >2500 different mutations and
therefore represents a toolset and workflow that supports
mutation discovery on multiple templates from a single
blood draw.

Evaluation of template quality
Interpreting NGS data rests on a clear understanding
of the quality of template that is being interrogated. A
sequencing pipeline was designed supporting case control
detection of single point variants to 1% (Supplementary
Figure S1). A primary distinguishing feature between
ccfDNA and ctcDNA is the fragmented nature of the
ccfDNA that has been described and observed previously
[29, 30]. For the purposes of this experiment, the variance
of amplification efficiency manifest in the ccfDNA
demonstrated that approximately half of the amplicons in
ccfDNA amplified the target sequence less efficiently than
control (Supplementary Figure S2). To ensure sufficient
coverage of the fragmented template, we therefore
decided to devote one 318 chip to the analysis of each
ccfDNA sample.
A second characteristic distinguishing ccfDNA
and cell based DNA sequence came from the evaluation
of the SNV substitution frequency (SNV-SF). The SNVSF results in a quality metric that can be used to evaluate
accuracy and precision as well as process-associated or
biologically-associated noise and was used as a general
metric for mutation frequency. To evaluate SNV-SF,
template from the different compartments recovered
from a single sample were evaluated using the AmpliSeq
hotspot panel. After alignment, the template specific
libraries were compared to germline sequence and only
alterations with >2000 reads were evaluated. However,
the reportable range for SNV-SF determination was not
restricted to the Cosmic identified SNV in the Hotspot
library. Therefore, any alteration detected that could not
be eliminated by comparison to germline was included.
This general calculation gives a comparison of different
sample types from the same patient.
www.impactjournals.com/oncotarget

Clinical sequence output: Primary comparison
of different templates
An important measure for clinical relevance of a
NGS test is the detection of disease associated alterations
in templates derived from tumor sample. This experiment
was conducted on a cohort of metastatic breast cancer
samples. After assembly, all variants were filtered to
yield COSMIC validated mutations. For cell enrichment,
we initially included EpCAM based recovery to compare
capture to a cocktail of EpCAM/Her2/Trop2. As shown
in Supplementary Table S1, the frequency with which
EpCAM capture alone supported identification of
mutation bearing cells was 9%. The EMT cocktail
outperformed the EpCAM only capture by 3-fold (Table
3). Therefore, these data focus on characterizing the
EMT performance.
The ctcDNA and ccfDNA samples were analyzed
using a case-control model with a limit of detection of
1%. For FFPE, no case-control was used and the limit
of detection was 10%. The incidence for detection of
variants in evaluable FFPE samples using the AmpliSeq
panel was 54% (14 of 26 with 6 samples QNS). The
genes most frequently mutated were TP53 and PIK3CA
with mutation frequencies of 20 and 28% respectively.
This is consistent with these being the most frequently
altered genes in breast cancer. The frequency of mutations
observed in ccfDNA and EMT ctcDNA samples was
48% and 25% respectively. Similar to the FFPE analysis,
the most frequently altered genes were again TP53 and
26728
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PIK3CA. Specifically, mutations in TP53 and PIK3CA
were detected with 16% and 9% frequency respectively in
the ctcDNA from 32 evaluated samples. Mutations in the
same genes were observed with 29% and 16% frequency
in ccfDNA. In combination, ccfDNA and EMT ctcDNA
produced SNV information 56% of the time - a frequency
directly comparable to the FFPE sample frequency of
58%. Therefore overall, the peripheral multitemplate
analysis produces signal with 98% of the frequency of
evaluable FFPE samples.

The impact of sampling on heterogeneity can
be observed both within a sample type as between
compartments. For instance, sample CYN-026 described a
TP53 (C182Y) mutation in a bone marrow derived biopsy
sample. A synchronous bone marrow sample displayed
a distinct TP53 alteration (G108S) as well as alterations
in APC (G1447*) and PIK3CA (H1047R). The PIK3CA
alteration but neither of the TP53 or the APC alterations
were detected in the peripheral samples. Furthermore, the
PIK3CA alteration was detected in the EMT population

Table 2: Target cell recovery performance
CK+ cells/7.5mL
Capture Cocktail

CK+ purity
(%CK+)

CD45+/
DAPI+/7.5mL

Median

sd

Average

Range

Median

EpCAM

8.0

20.3

7.7%

1 - 112

116

EpCAM/Her2/Trop2

23.5

88.4

8.8%

2 - 487

172

Figure 2: Evaluation of template noise in cell free DNA and cells enriched from blood as measured by SNV-SF
Circulating epithelial cell DNA (cecDNA) or matched cell free DNA was recovered from 29 normal healthy donors.
Paired template were sequenced using the AmpliSeq library and compared to germline sequence from the same sample. Alterations with an
extended reportable range to include all evaluated bases in the library were enumerated. A two-tailed Wilcoxon rank sum test measured a
mean difference of 3.0 and a p value of 0.0009.
www.impactjournals.com/oncotarget
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Table 3: COSMIC identified SNV from matched tumor samples derived from blood or biopsy
ID

E/P/H

ctcDNA

ccfDNA

FFPE 1

C293-001

+/+/-

X

X

X

C293-002

-/-/+

TP53; p.E285K

X

QNS tissue

C293-003

-/-/+

X

X

X

C293-004

+/-/-

X

PIK3CA;p.E542K

PIK3CA;p.E542K

C293-005

+/-/+

X

PIK3CA; p.V344G

PIK3CA; p.V344G

ERBB2; p.V777L

ERBB2; p.V777L

C293-006

-/-/-

X

TP53;p.H193R

TP53;p.H193R

C293-007

-/-/-

X

X

KRAS; V14I

C293-008

NA

X

TP53; p.S215R

QNS tissue

C293-009

+/+/Eq

X

X

X

C293-010

+/-/+

TP53; p.Y163D

TP53; p.Y163D

QNS Tissue

C293-011

-/-/-

X

TP53; p.R175H

TP53; p.R175H

C293-012

+/-/-

X

X

X

C293-013

+/+/-

X

QNS DNA

PIK3CA; p.H1047R

C293-014

+/+/Eq

X

TP53; p.M246I

X

C293-015

-/-/-

X

X

X

C293-016

-/-/+

PIK3CA; p.E545K

X

QNS Tissue

C293-018

+/-/-

PIK3CA;
p.H1047R

PIK3CA; p.H1047R

QNS DNA

C293-019

+/+/-

X

X

IDH2; p.R140Q

C293-020

-/-/-

X

X

X

C293-021

+/+/-

X

GNAQ; Q209K

X

C293-022

+/+/-

X

X

PIK3CA; p.E545K

C293-023

-/+/Eq

TP53; p.R175H

TP53; p.R175H

TP53; p.R175H

C293-024

+/-/-

X

PIK3CA; p.H1047R

X

C293-025

+/-/-

X

X

X

C293-026

+/-/Eq

PIK3CA;
p.H1047R

PIK3CA; p.H1047R

TP53; p.C182Y

FFPE 2

PIK3CA;p.E542K

X

PIK3CA;
p.H1047R

PIK3CA;
p.H1047R

APC; p.Q1447*
TP53; p.G108S
PIK3CA;
p.H1047R

C293-027

+/+/-

TP53; p.H178P

X

X

C293-028

+/-/-

X

X

QNS DNA

C293-029

-/-/+

X

TP53; p.E286K

QNS DNA

C293-030

+/+/-

X

X

ERBB2; V777L

C293-031

+/+/-

X

X

X
(Continued )

www.impactjournals.com/oncotarget

26730

Oncotarget

ID

E/P/H

ctcDNA

ccfDNA

FFPE 1

C293-032

-/-/-

X

TP53; p.Y107*

X

C293-033

+/+/-

TP53; p.C176F

TP53; p.C176F

TP53; p.C176F

FFPE 2

TP53; p.C176S
Most recent hormonal (ER/PR) and Her2 status is included where available (E/P/H) and indicated as present (+), absent
(-), or equivocal (Eq). Alterations are indicated by the target gene and the predicted impact. Samples with no detectable
alteration at the limit of detection are indicated by X. Samples that were quantity not sufficient (QNS) are indicated.

DISCUSSION

but not the epithelial population. In another sample
(CYN-003) a mutation in PIK3CA (E542K) is detected
in two biopsy samples and the ccfDNA compartment but
is not detected in either the epithelial or EMT cells. In
contrast, CYN-016 identifies a PIK3KCA (E545K) driver
mutation in EMT cells that is not detected in ccfDNA.
The biopsy sample for the latter subject had insufficient
tumor tissue on pathology review for sequence analysis.
Thus, whether sampling different biopsy sites or different
peripheral compartments, the three different templates are
complementary.
Evaluating the impact of different tumor sampling
mechanisms has been challenging due to limited studies
capable of making direct comparisons between samples
and indexing the template quality and performance on
different templates but with the same assay. Due to the
impact of insufficient biopsy material (QNS), mutations
were described in 47% of the FFPE samples (26 evaluable
samples of 32 subjects). Of that number, 9 samples (28%)
produced peripheral signal from either ccfDNA or ctcDNA
or both that was concordant with FFPE. Separately,
while 72% of the samples have some information in one
compartment or the other, 44% (10 of 23 samples) of any
alteration could be confirmed in an orthogonal template
(Table 3).
The relationship between the different sampling
mechanisms is described in Figure 3. The orthogonal
nature of the three sampling mechanisms detected is
impacted both by the different source of sample as
well as the chance that no tumor derived material is
detected in either FFPE or the peripheral samples. The
overlap of SNV mutation calls between sample types
(FFPE, ctcDNA, ccfDNA) was compared. Concordant
results were measured as the presence of any specific
mutation between different sample types in the same
patient. There were clinically relevant and potentially
actionable mutations detected in EMT ctcDNA samples
or ccfDNA samples that were not shared with other
sample types. Thus EMT ccfDNA and ccfDNA produce
complementary data that can supplement rare signals
in either compartment or can serve as orthogonal
confirmatory templates. Furthermore, the ability to tune
the informative cell population can dramatically alter the
frequency of informative reads.

www.impactjournals.com/oncotarget

In this prospective study, we compared NGS data
sets from three distinct patient-matched samples types
(FFPE, ctcDNA, ccfDNA). A common amplicon based
resequencing panel (Ampliseq v2 HotSpot panel) was
used for all template types in a NGS pipeline using
identical variant analysis. Patients with available quality
tissue specimen from diagnostic biopsy were isolated and
compared. We demonstrated that ccfDNA and ctcDNA
evaluation yields complementary molecular information
from the same blood sample. Moreover, the capture of
CTC for molecular analysis may be tuned based on a
molecular detection system. In fact, the capture protocol
for circulating mutation bearing cells was a novel cocktail
of anti-EpCAM, Her2, and Trop2 antibodies. This cocktail
was designed based on the established role of EpCAM in
defining a population of cells in blood that is prognostically
related to disease progression as well as metastatic events
[31, 32]. The additional markers have established an
emerging utility for antibody directed therapies in breast
cancer targeting Her2 and Trop2 respectively [33-36].
While other cocktails have been tested, only a subset
has been shown to be productive for the detection of
mutation bearing cells [11, 37]. Furthermore, in our study
the detection and molecular analysis of CTCs was not
dependent on clinical or biological outcome to interpret
the value of the populations. Specifically, the CellSearch
test is not dependent only on EpCAM expression per se.
Rather, if anything changes, including cells or reagents, the
approved prognostic value is lost. For these applications,
the most important result is the demonstration that the
informative template from a blood sample may now be
defined molecularly as related to the disease process by
orthogonal characterization of DNA alterations. DNA
based analysis of SNV was utilized to demonstrate
qualitative characteristics between the different template
compartments. Having validated the capture definition,
the informative cell population may now be interrogated
for additional biomarkers of value such as expression of
protein markers [38], protein modification events, or RNA
expression based analysis for biomarkers that are opaque
in the DNA compartment such as the AR-V7 splice variant
in prostate cancer [39].
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The additional goal of these comparisons was to
evaluate different template compartments for the ability
to provide clinically useful DNA sequence information.
The measures of success for these comparisons were
deemed to be i) the frequency of disease associated
alterations observed in the analysis of multiple
templates (tissue, ctcDNA or ccfDNA) and ii) the
quality of template for supporting sequence analysis.
A key observation is that the FFPE sample and the
complementary peripheral samples together provide
molecular information in a similar proportion of samples.
In these data, all templates are detecting alterations
within a two-fold range of each other. Previous studies
comparing CTC and ccfDNA have been limited by
making comparisons with different technologies [21]
or using shared readouts that do not alter the significant
signal to noise challenge of detecting rare mutation
bearing cells [23]. These approaches made it challenging
to perform a direct comparison of ccfDNA and ctcDNA.
A recent report demonstrating the presence of a T790M
resistance mutation in lung cancer supports the data
presented here in that ctcDNA and ccfDNA produce
complementary information [26].

Fundamental to this experiment is the ability to
clarify the population of cells molecularly. There are
numerous approaches to recovering tumor cells from
blood samples ranging from size based selection, to
mechanical mechanisms, charge based approaches or
no selection. Each has applications for discovery of
previously uncharacterized cell populations. In a patient
setting, population based (as opposed to single cell)
analysis of cells or ccfDNA fragments allows more rapid
molecular analysis but also uses a sampling mechanism
that may be less sensitive to analytic variables. A
significant advantage of positive selection approaches is
the ability to standardize the enrichment definition around
a standardizable biological definition.
The studies reported here are based upon the
examination of cell pools, as well as mixtures of
ccfDNA isolated from whole blood. To the best of our
knowledge, there are no published data that show a
population of tumor cells in blood can be productively
recovered and sequenced directly yielding a clinically
relevant mutational spectrum. Other direct evidence
for the significant presence of mutation bearing cells
has come from single cell experiments or single cell

Figure 3: COSMIC identified SNV from matched tumor samples derived from blood or biopsy. Alterations are counted in

all clinical samples. Overlap between each template is depicted by Venn diagram with comparison between FFPE, ccfDNA and ctcDNA
compartments.
www.impactjournals.com/oncotarget
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based readouts such as FISH analysis [10, 40-42].
Despite that, a number of studies demonstrated the
presence of cells in blood that contain mutations that
can be tracked back to the tumor but almost all are
restricted single cell selection [43], single cell analysis
[44, 45], or single cell propagation steps [11, 37]. The
population based approach we present in this paper
supports high throughput based analysis. In addition,
a median background of 172 CD45+ events from a
7.5mL blood sample will allow detection of as few as
3-4 heterozygous events from a blood sample using a
test that can detect mutations with a 1% frequency; a
performance already approaching a single cell detection
event. Furthermore, individuals without cancer exhibit
recoverable cells with a phenotype related to circulating
epithelial cells [46, 47]. However these cells do not bear
cancerous SNV mutations. It will be important therefore
to develop advanced validation tools, like detection of
DNA alterations, before further characterization of cell
populations with tools such as expression profiling.
Even enumeration has to be indexed to a clinically
prognostic impact or molecular demonstration that the
cell population is truly tumor derived.
The current data demonstrate that both blood
derived templates support informative amplicon based
resequencing. However, significant differences between
the templates with respect to their performance in NGS
variant analysis suggest that the templates need to be
handled according to their strengths and weaknesses
by standardizing the analysis rules. Key among these
observations was the demonstration of a variant noise
detected in the ccfDNA that is significantly elevated
over cell based analysis from the same sample. This
noise was detected at random sites within the amplicon
that are not associated with the disease process
and need to be eliminated by a restriction call using
bioinformatic methods. This has implications for the
ability to use this approach to map de novo mutations
discovered in the ccfDNA template. One hypothesis
to explain this noise, postulates that noise is due to
the fixative or preservative utilized, analogous to
the template damage observed with FFPE template
[48]. However the absence of a similar noise profile
in other matched DNA templates recovered from the
same sample argues against this hypothesis. ccfDNA
is a degradative product of catabolism, present in the
extracellular compartment and therefore is susceptible
to multiple processes of damage in plasma. Indeed,
when specifically evaluated, a similar background has
been described elsewhere [49]. Alternatively, given the
data suggesting accumulation of DNA damage over
time in preneoplastic tissues, we can speculate that this
template associated noise might be a reflection of that
larger phenomenon in biology, in essence detecting a
level of “normal” DNA damage even in the absence
of diagnosed malignancies with potential implications
www.impactjournals.com/oncotarget

for future studies [50-52]. Certainly, this difference
between ctcDNA and ccfDNA quality reflects the
known differences in their biological source and has
implications for the prognostic value of each biomarker
[53].
Clearly, detection of tumor related events depend
on the targets included in the NGS test. The AmpliSeq
v2 Hotspot panel is a well curated pan-cancer panel that
has been shown to identify disease associated alterations
in FFPE and ccfDNA [54-56]. The most frequently
mutated alterations in breast cancer are detected with
related frequencies in the multiple templates. However,
not all disease associated mutations can be included in
any targeted panel. More comprehensive whole genome
or whole exome sequencing is possible but should be
considered in the context of the enzymatic amplification
steps necessary to produce sufficient template from
limiting numbers of cells and the impact on sequence
integrity. Therefore, it will be key to develop detection
tools that reflect the most relevant decision points for
any given patient population. For instance, in breast
cancer, there are clinically relevant biomarker targets
in the protein, RNA or DNA compartments [57-63].
Functional access to both ccfDNA and CTC based
templates supports development of protein and RNA
based readouts in addition to detection of DNA based
alterations.
This study demonstrates that it is possible to
productively interrogate both populations of mutation
bearing cells enriched from a blood sample and
ccfDNA. Importantly, this analysis does not require
a priori knowledge of the mutations present and
will serve as a useful discovery tool. Expanding the
definition of informative cell populations may now be
indexed to a molecular definition. This ability to define
populations beyond the legacy epithelial definition
raises the possibility of informative biomarkers in
non-epithelial settings such as soft tissue cancers,
skin cancers such as melanoma, or epithelial cancers
that have not previously performed well with strictly
epithelial markers but still characterized by metastatic
events.
Fundamentally, tumor derived samples from biopsy,
circulating tumor cell populations and ccfDNA are
acquired by different sampling mechanisms; mechanisms
that capture different moments of the disease and
potentially not necessarily the same biological sources.
The study of these alternate templates by next generation
sequencing technologies has emphasized the clonal nature
of cancer and the impact of evaluating these different
biopsy sites [64]. The emerging model for the peripheral
templates suggest ccfDNA samples the genomic DNA
fragments released from all tumor sites. In contrast,
circulating tumor cells are clearly related to the disease
process, predict more aggressive disease and increased
metastasis [65]. As such, CTC reflect the mobile and
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metastatic subset of tumor cells. Clearly the overlap
between detectable alterations in each compartment
demonstrates the relevant information may not always
be linked to one specific compartment or one biology. An
ability to evaluate multiple compartments, both in terms
of sensitivity and biomarker definition, is an innovative
approach that can have significant impact with regards
to diagnosis and on our capacity to better understand
the various biological processes driving metastases and
potentially different therapeutic approaches. The impact
of these biological differences will have to be determined
in prospective studies.

fixative. A white blood cell control was recovered from
0.1cc of the original sample. Plasma was collected after
brief centrifugation to separate cellular components.
CTC’s were enriched as described [25]. In brief, the
cellular component in the starting blood volume was
blocked with FcR block and labelled with a biotinylated
antibody cocktail consisting of anti-EpCAM alone, or in
combination with anti-HER2, and anti-TROP2 (Cynvenio
Biosystems) followed by iMAG streptavidin beads. The
labeled blood was processed in the CTC flow cell on the
LiquidBiopsy platform (Cynvenio Biosystems). Captured
cells were characterized by evaluating immunofluorescent
staining with anti-Cytokeratin, anti-CD45 and DAPI.
Captured cells were recovered by centrifugation to
produce an enriched cell pellet. The CTC pellet was
digested as described [25] and the resulting digest was
diluted to 12μL with TE. The AmpliSeq library reagents
were added directly to the template and further processed
as for the germline and ccfDNA samples.
For enrichment of ccfDNA from the recovered
plasma, the QIAamp Circulating Nucleic Acid Kit was
used along with the QIAVAC system as recommended by
the manufacturer (Qiagen, Valencia, CA). DNA resulting
from this purification was quantitated on a Nanodrop
(Thermo Fisher Scientific) and directly utilized for
sequencing library generation. ccfDNA libraries were
produced with a 10 ng input of ccfDNA.
FFPE processed slides were H&E stained, graded
by pathologist to indicate the area of specific tumor tissue,
macro-dissected, and placed into individual tubes. Three to
six 5μm thick sections were processed using the Agencourt®
FormaPure® kit (Beckman Coulter). Samples were eluted
in 45μL and DNA was concentrated further with Agencourt
AMPure XP beads to yield a final DNA volume of 15μL.
DNA concentration was measured by Qubit® dsDNA HS
(High Sensitivity) Assay Kit (Thermo Fisher Scientific).

MATERIALS AND METHODS
Ethics statement
This prospective clinical trial was funded with a
NIH/NCI contract with the express purpose of expanding
the definition of evaluable tumor cells in blood. The long
term goal of the SBIR contract was to develop new devices
and methods of CTC detection with a focus on clinical
tools rather than research based approaches. Patients were
enrolled at three different sites (Kimmel Cancer Center of
Thomas Jefferson University, Winship Cancer Institute of
Emory University, and The West Clinic). Normal human
donor blood was purchased from HemaCare Corporation.
All subjects provided written informed consent under an
Institutional Review Board approved protocols.

Study subjects
The study was designed to enroll subjects with a
confirmed diagnosis of metastatic breast cancer that were
about to start a new line of therapy for their disease. A
tissue biopsy of the metastatic lesion was mandatory.
After appropriate consent enrolled subjects provided a
blood sample before starting the new therapy. The blood
samples had a minimum volume of 16mL minimum from
two K2-EDTA tubes with minimal signs of hemolysis.
Samples were processed for recovery of CTC populations
within 96 hours using a CLIA approved process. Thirtytwo metastatic breast cancer patients were recruited. FFPE
and blood was recovered from each donor. From the blood
samples, germline white blood cell DNA (wbcDNA),
ccfDNA, and ctcDNA were isolated. Sequencing libraries
were constructed from the matched samples and subjected
to NGS using the IonTorrent PGM platform.

Sequencing data analysis
Primary sequence was demultiplexed and exported
from the Torrent Server as FASTQ. The FASTQ files were
aligned by reference guided assembly to NCBI GRCh37
p5 using Bowtie 2 [66]. Post-assembly alignments were
piled and curated for accuracy using SAM Tools (version
0.1.19) [67] and transferred to Perl using Bio::DB::Sam.
ctcDNA and ccfDNA templates were analyzed and a
mutation was called if ≥20 mutant reads were observed for
a limit of detection (LOD) of 1%. FFPE templates were
analyzed to a LOD of 10%. ctcDNA and ccfDNA analysis
was based upon a case-control model for variant detection,
in which total read coverage must be ≥ 2000 reads per
amplicon for ctcDNA and ccfDNA sample and validated
calls were required to be absent from the negative control
wbcDNA sequence (Supplementary Figure S1). FFPE
analysis was not case-controlled, and total read coverage
threshold was ≥ 500 reads per amplicon.

Template enrichment procedures
All sample processing, sequencing and analysis was
performed in the Cynvenio Biosystems CAP approved
facility (Westlake Village, CA) under CLIA supervision.
Whole blood was collected in purple top (K2EDTA) tubes
and stabilized using LiquidBiopsy (Cynvenio Biosystems)
www.impactjournals.com/oncotarget
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